Doxorubicin promotes transcriptional upregulation of Cdc25B in cancer cells by releasing Sp1 from the promoter

Oncogene

Volumn 32, Issue 42, 2013, Pages 5123-5128

  Dalvai, M ^a,b   Mondesert, O ^b,c   Bugler, B ^b,d   Manenti, S ^b,e,f   Ducommun, B ^b,c,g   Dozier, C ^b,e,f  

^a Université Paul Sabatier   (France)

^b UNIVERSITÉ DE TOULOUSE   (France)

^c CNRS   (France)

^d Université de Toulouse Paul Sabatier   (France)

^e CHU PURPAN   (France)

^f CANCER RESEARCH CENTER OF TOULOUSE   (France)

^g TOULOUSE UNIVERSITY HOSPITAL   (France)

Author keywords

Cdc25B; Doxorubicin; P53; Sp1

Indexed keywords

ANTHRACYCLINE; CASPASE 3; CHECKPOINT KINASE 2; DOXORUBICIN; ETOPOSIDE; MESSENGER RNA; NUCLEAR FACTOR Y; PROTEIN P53; PROTEIN TYROSINE PHOSPHATASE; TRANSCRIPTION FACTOR SP1;

ARTICLE; CANCER CELL; CARCINOMA CELL; CHROMATIN IMMUNOPRECIPITATION; COLON CARCINOMA; CONTROLLED STUDY; DNA DAMAGE; ENZYME PHOSPHORYLATION; GENE PRODUCT; GENOMIC FRAGMENT; HUMAN; HUMAN CELL; IONIZING RADIATION; LUNG NON SMALL CELL CANCER; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN DEGRADATION; RNA INTERFERENCE; TRANSCRIPTION INITIATION; TRANSCRIPTION REGULATION; UPREGULATION;

ANTIBIOTICS, ANTINEOPLASTIC; CCAAT-BINDING FACTOR; CDC25 PHOSPHATASES; DNA DAMAGE; DOXORUBICIN; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, P53; HCT116 CELLS; HUMANS; PROMOTER REGIONS, GENETIC; SP1 TRANSCRIPTION FACTOR; UP-REGULATION;

EID: 84886094526     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2012.524     Document Type: Article

References (33)

1. Boutros R, Dozier C, Ducommun B. The when and wheres of CDC25 phosphatases. Curr Opin Cell Biol 2006; 18: 185-191. (Pubitemid 43375887)
2. Lindqvist A, Kallstrom H, Lundgren A, Barsoum E, Rosenthal CK. Cdc25B cooperates with Cdc25A to induce mitosis but has a unique role in activating cyclin B1-Cdk1 at the centrosome. J Cell Biol 2005; 171: 35-45. (Pubitemid 41434600)
3. Galaktionov K, Lee AK, Eckstein J, Draetta G, Meckler J, Loda M et al. CDC25 phosphatases as potential human oncogenes. Science 1995; 269: 1575-1577.
4. Kang CM, Cho HN, Ahn JM, Lee SS, Jeoung DI, Cho CK et al. Alteration of gene expression during radiation-induced resistance and tumorigenesis in NIH3T3 cells revealed by cDNA microarrays: involvement of MDM2 and CDC25B. Carcinogenesis 2004; 25: 123-132.
5. Yao Y, Slosberg ED, Wang L, Hibshoosh H, Zhang YJ, Xing WQ et al. Increased susceptibility to carcinogen-induced mammary tumors in MMTV-Cdc25B transgenic mice. Oncogene 1999; 18: 5159-5166. (Pubitemid 29460651)
6. Boutros R, Lobjois V, Ducommun B. CDC25 phosphatases in cancer cells: key players? Good targets? Nat Rev Cancer 2007; 7: 495-507. (Pubitemid 46985396)
7. Karlsson-Rosenthal C, Millar JB. Cdc25: mechanisms of checkpoint inhibition and recovery. Trends Cell Biol 2006; 16: 285-292. (Pubitemid 43868088)
8. Aressy B, Bugler B, Valette A, Biard D, Ducommun B. Moderate variations in CDC25B protein levels modulate the response to DNA damaging agents. Cell Cycle 2008; 7: 2234-2240. (Pubitemid 352031526)
9. Bugler B, Quaranta M, Aressy B, Brezak MC, Prevost G, Ducommun B. Genotoxicactivated G2-M checkpoint exit is dependent on CDC25B phosphatase expression. Mol Cancer Ther 2006; 5: 1446-1451. (Pubitemid 44070480)
10. Miyata H, Doki Y, Yamamoto H, Kishi K, Takemoto H, Fujiwara Y et al. Overexpression of CDC25B overrides radiation-induced G2-M arrest and results in increased apoptosis in esophageal cancer cells. Cancer Res 2001; 61: 3188-3193. (Pubitemid 32691974)
11. Bansal P, Lazo JS. Induction of Cdc25B regulates cell cycle resumption after genotoxic stress. Cancer Res 2007; 67: 3356-3363. (Pubitemid 46724875)
12. Jullien D, Bugler B, Dozier C, Cazales M, Ducommun B. Identification of N-terminally truncated stable nuclear isoforms of CDC25B that are specifically involved in G2/M checkpoint recovery. Cancer Res 2011; 71: 1968-1977.
13. Lemaire M, Froment C, Boutros R, Mondesert O, Nebreda AR, Monsarrat B et al. CDC25B phosphorylation by p38 and MK-2. Cell Cycle 2006; 5: 1649-1653. (Pubitemid 44285251)
14. Dalvai M, Mondesert O, Bourdon JC, Ducommun B, Dozier C. Cdc25B is negatively regulated by p53 through Sp1 and NF-Y transcription factors. Oncogene 2011; 30: 2282-2288.
15. Korner K, Jerome V, Schmidt T, Muller R. Cell cycle regulation of the murine cdc25B promoter: essential role for nuclear factor-Y and a proximal repressor element. J Biol Chem 2001; 276: 9662-9669.
16. Scian MJ, Carchman EH, Mohanraj L, Stagliano KE, Anderson MA, Deb D et al. Wild-type p53 and p73 negatively regulate expression of proliferation related genes. Oncogene 2008; 27: 2583-2593. (Pubitemid 351550876)
17. Zhao H, Watkins JL, Piwnica-Worms H. Disruption of the checkpoint kinase 1/cell division cycle 25A pathway abrogates ionizing radiation-induced S and G2 checkpoints. Proc Natl Acad Sci USA 2002; 99: 14795-14800. (Pubitemid 35334563)
18. Wang B, Xiao Z, Ko HL, Ren EC. The p53 response element and transcriptional repression. Cell Cycle 2010; 9: 870-879.
19. Rashi-Elkeles S, Elkon R, Shavit S, Lerenthal Y, Linhart C, Kupershtein A et al. Transcriptional modulation induced by ionizing radiation: p53 remains a central player. Mol Oncol 2011; 5: 336-348.
20. St Clair S, Giono L, Varmeh-Ziaie S, Resnick-Silverman L, Liu WJ, Padi A et al. DNA damage-induced downregulation of Cdc25C is mediated by p53 via two independent mechanisms: one involves direct binding to the cdc25C promoter. Mol Cell 2004; 16: 725-736. (Pubitemid 39586531)
21. Xiao Z, Chen Z, Gunasekera AH, Sowin TJ, Rosenberg SH, Fesik S et al. Chk1 mediates S and G2 arrests through Cdc25A degradation in response to DNAdamaging agents. J Biol Chem 2003; 278: 21767-21773. (Pubitemid 36792580)
22. Baldin V, Cans C, Knibiehler M, Ducommun B. Phosphorylation of human CDC25B phosphatase by CDK1-cyclin A triggers its proteasome-dependent degradation. J Biol Chem 1997; 272: 32731-32734. (Pubitemid 28023602)
23. Bu Y, Suenaga Y, Ono S, Koda T, Song F, Nakagawara A et al. Sp1-mediated transcriptional regulation of NFBD1/MDC1 plays a critical role in DNA damage response pathway. Genes Cells 2008; 13: 53-66.
24. Uchida Y, Itoh M, Taguchi Y, Yamaoka S, Umehara H, Ichikawa S et al. Ceramide reduction and transcriptional up-regulation of glucosylceramide synthase through doxorubicin-activated Sp1 in drug-resistant HL-60/ADR cells. Cancer Res 2004; 64: 6271-6279. (Pubitemid 39129431)
25. Xu J, Zhou JY, Wei WZ, Philipsen S, Wu GS. Sp1-mediated TRAIL induction in chemosensitization. Cancer Res 2008; 68: 6718-6726.
26. Chu S. Transcriptional regulation by post-transcriptional modification-Role of phosphorylation in Sp1 transcriptional activity. Gene 508: 1-8.
27. Beishline K, Kelly CM, Olofsson BA, Koduri S, Emrich J, Greenberg RA et al. Sp1 facilitates DNA double-strand break repair through a nontranscriptional mechanism. Mol Cell Biol 2012; 32: 3790-3799.
28. Iwahori S, Yasui Y, Kudoh A, Sato Y, Nakayama S, Murata T et al. Identification of phosphorylation sites on transcription factor Sp1 in response to DNA damage and its accumulation at damaged sites. Cell Signal 2008; 20: 1795-1803.
29. Olofsson BA, Kelly CM, Kim J, Hornsby SM, Azizkhan-Clifford J. Phosphorylation of Sp1 in response to DNA damage by ataxia telangiectasia- mutated kinase. Mol Cancer Res 2007; 5: 1319-1330.
30. Bocangel D, Sengupta S, Mitra S, Bhakat KK. p53-Mediated down-regulation of the human DNA repair gene O6-methylguanine-DNA methyltransferase (MGMT) via interaction with Sp1 transcription factor. Anticancer Res 2009; 29: 3741-3750.
31. Cuesta A, Zambrano A, Royo M, Pascual A. The tumour suppressor p53 regulates the expression of amyloid precursor protein (APP). Biochem J 2009; 418: 643-650.
32. Thompson T, Tovar C, Yang H, Carvajal D, Vu BT, Xu Q et al. Phosphorylation of p53 on key serines is dispensable for transcriptional activation and apoptosis. J Biol Chem 2004; 279: 53015-53022. (Pubitemid 40051800)
33. Szulawska A, Gniazdowski M, Czyz M. Sequence specificity of formaldehydemediated covalent binding of anthracycline derivatives to DNA. Biochem Pharmacol 2005; 69: 7-18. (Pubitemid 39592867)